Physician profile
Marshall A Staton
NPI 1780635292
$5,589.17
in general payments reported to CMS, 2019-2025
22 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $753 · 2021: $813 · 2022: $647 · 2023: $1,060 · 2024: $1,272 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,725.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,724.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $880.30 | 2022-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $871.03 | 2019-2025 | Rexulti |
| Abbvie INC. | $836.75 | 2021-2025 | Vraylar |
| Axsome Therapeutics, INC. | $439.88 | 2023-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $362.32 | 2021-2025 | Trintellix |
| Corium, LLC | $287.10 | 2023-2024 | Azstarys |
| Lundbeck LLC | $265.66 | 2019-2023 | Rexulti |
| Adlon Therapeutics L.P. | $249.83 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $216.45 | 2019-2020 | |
| Inari Medical, INC. | $196.36 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Pharmaceuticals, INC | $177.12 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $137.45 | 2024-2025 | Cobenfy |
| Eisai INC. | $125.00 | 2021 | |
| Ethicon INC. | $117.89 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $104.05 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.00 | 2024 | Caplyta |
| Neos Therapeutics, LP | $87.65 | 2020-2021 | |
| Allergan, INC. | $53.74 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $32.23 | 2021 | |
| Idorsia Pharmaceuticals US INC | $25.00 | 2022 | |
| Shire North American Group INC | $12.14 | 2019 | |
| Ironshore Pharmaceuticals INC. | $11.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Staton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.